Hao He
Fuzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Prognosis and risk factors for pathological non-response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma.
Journal: Frontiers in immunology
Published: February 22, 2026
Prognostic Significance of the T12-SMI Before and After Neoadjuvant Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma.
Journal: Annals of surgical oncology
Published: January 23, 2026
Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer.
Journal: Cancer letters
Published: December 17, 2025
Surgical Outcomes of Robotic, Minimally Invasive, and Open Esophagectomy After Neoadjuvant Therapy: a Propensity Score-Matching Study.
Journal: Annals of surgical oncology
Published: September 02, 2025
METTL3-mediated m6A methylation of LncRNA DUXAP8 promoted esophageal squamous cell carcinoma progression by activating the PI3K/AKT signaling pathway.
Journal: Cell division
Published: July 30, 2025
CT imaging is a feasible method for the preoperative prediction of the main pathologic response after neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma.
Journal: Updates in surgery
Published: July 28, 2025
Postoperative chemotherapy versus surgery alone in esophageal squamous cell carcinoma: A single-center propensity-matched survival analysis.
Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: July 12, 2025
Machine learning and the nomogram as the accurate tools for predicting postoperative malnutrition risk in esophageal cancer patients.
Journal: Frontiers in nutrition
Published: April 05, 2025
Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO).
Journal: Nature communications
Published: December 05, 2024
Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy in patients with borderline resectable esophageal squamous cell carcinoma.
Journal: Journal of translational medicine
Published: October 30, 2024
A-to-I-Edited miR-1304-3p Inhibits Glycolysis and Tumor Growth of Esophageal Squamous Cell Carcinoma by Inactivating Wnt5a/ROR2 Signaling.
Journal: Molecular carcinogenesis
Published: September 14, 2024
Last Updated: 09/26/2026